iStent yields greatest IOP reduction in eyes with highest baseline pressure

FORT LAUDERDALE, Fla. — IOP reduction correlated strongly with preoperative IOP in patients who underwent cataract surgery with iStent implantation, according to a scientific poster presented at the American Glaucoma Society meeting here.“The increased efficacy of the iStent among glaucoma patients with higher pressures means that those who need IOP reduction the most will experience the greatest benefit,” Reay H. Brown, MD, and colleagues wrote. “Longer follow-up shows that patients with IOP greater than 21 mm Hg have a substantial IOP reduction that persisted to almost 2 years. Patients with (Read more...)

Second Sight to Present at the 28th Annual ROTH Conference on March 14, 2016

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced that Will McGuire, President and Chief Executive Officer, will present at the 28th Annual ROTH Conference as follows: Date:     Monday, March 14, 2016 Time: 2:00 p.m. PST (5:00 p.m. EST) Location: The Ritz-Carlton, Laguna Niguel, Salon 2 – BLU